

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

UNAUDITED FINANCIAL RESULTS OF CR DOUBLE-CRANE FOR THE SIX MONTHS ENDED 30 JUNE 2023

On 23 August 2023, CR Double-Crane released its interim report for the six months ended 30 June 2023.

China Resources Double-Crane Pharmaceutical Co., Ltd. (華潤雙鶴藥業股份有限公司) (“**CR Double-Crane**”) is a company incorporated in the People’s Republic of China. The shares of CR Double-Crane are listed on the Shanghai Stock Exchange. As of the date of this announcement, CR Double-Crane is indirectly owned as to 59.99% by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and is a subsidiary of the Company.

On 23 August 2023, CR Double-Crane released its interim report for the six months ended 30 June 2023 (the “**CR Double-Crane Unaudited Financials**”). Set out below is the key financial information of the CR Double-Crane Unaudited Financials:

	As of 30 June 2023 (RMB) (unaudited)	As of 31 December 2022 (RMB) (audited)	Increase (%)
Total assets	15,126,705,942.34	14,482,536,656.83	4.45%
Net assets attributable to shareholders of the listed company	10,531,770,707.50	10,022,611,149.67	5.08%

	For the six months ended 30 June		Increase/ decrease
	2023 (RMB) (unaudited)	2022 (RMB) (unaudited)	(%)
Revenue	5,234,148,011.36	4,910,824,498.76	6.58%
Net profit attributable to the shareholders of the listed company	776,799,645.42	736,636,737.30	5.45%
Net profit attributable to the shareholders of the listed company (exclude extraordinary gains or losses)	722,372,024.58	691,905,809.78	4.40%
Net cash flow from operating activities	651,972,804.93	668,019,806.97	-2.40%
Basic earnings per share (RMB/share)	0.7554	0.7159	5.52%
Diluted earnings per share (RMB/share)	0.7554	0.7159	5.52%
Weighted average return on net asset (%)	7.49%	7.26%	0.23

percentage point

The CR Double-Crane Unaudited Financials have been prepared in accordance with the PRC Generally Accepted Accounting Principles, have not been reviewed or audited by the Company's auditors, and may require adjustment during the course of auditing. The financial information is limited to CR Double-Crane only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the CR Double-Crane Unaudited Financials, please refer to the interim report for the six months ended 30 June 2023 published by CR Double-Crane on the website of the Shanghai Stock Exchange (www.sse.com.cn).

By order of the Board of Directors
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Shenzhen, 24 August 2023

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong and Mr. Tao Ran as executive Directors, Mr. Lin Guolong, Mdm. Guo Wei, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.